Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2016, 25(1):22-30

Novel oral anticoagulants in treatment and secondary prevention of venous thromboembolism in current clinical practice: what is the message from the randomized clinical studies?

Remková A
I. interná klinika SZU a UNB, Lekárska fakulta SZU, Bratislava, Slovenská republika

The objective of anticoagulant treatment in patients with acute venous thromboembolism (VTE) is prevention of early death and recurrent symptomatic deep venous thrombosis/pulmonary embolism. Heparins and vitamin K antagonists (VKA) have been the mainstay of prevention and treatment of VTE for many years, but they have numerous limitations. In recent years, novel non-VKA oral anticoagulants (NOACs) have emerged as promising alternatives with the potential to overcome the limitations of traditional treatment of VTE. Clinical trials provided data on the efficacy and safety of the NOACs in comparison with standard care (heparin + VKA) in the acute treatment and secondary prevention of VTE as well as in comparison with placebo in extended VTE treatment. NOACs have been shown to be noninferior to VKA and heparin in the prevention and treatment of VTE. In extended VTE treatment, they are superior (more effective) to placebo. However, there are some differences in their safety profile (with respect to bleeding). This review specifically compares the design and results of the phase III trials with NOACs in VTE, reveals the differences in their use and discusses their implications in VTE treatment strategies.

Keywords: dabigatran; rivaroxaban; apixaban; recurrent venous thrombosis; pulmonary embolism bleeding

Published: January 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Remková A. Novel oral anticoagulants in treatment and secondary prevention of venous thromboembolism in current clinical practice: what is the message from the randomized clinical studies? Cardiology Letters. 2016;25(1):22-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kearon C, Akl EA, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S-e494S. Go to original source...
    2. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JSR, Huisman M, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk-Noordegraaf A, Zamorano JL, Zompatori M. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;3:3033-3073. Go to original source...
    3. Cohen AT, Imfeld S, Rider T. Phase III Trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: Comparison and critique of study methodology and results. Adv Ther 2014;31:473-493. Go to original source...
    4. McRae S. Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thrombosis Journal 2014;12:27. Go to original source...
    5. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriks­ son H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-2352. Go to original source...
    6. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le MF, Peter N, Kearon C. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129(7):764-772. Go to original source...
    7. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Büller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-2510. Go to original source...
    8. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bouna ­meaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-1297. Go to original source...
    9. Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799-808. Go to original source...
    10. Hokusai-VTE Investigators, Büller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-1415. Go to original source...
    11. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368(8):709-718. Go to original source...
    12. Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE,Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708. Go to original source...
    13. European Medicines Agency: Eliquis (apixaban) - Summary of Product Characteristics, August 2014, http://www.ema.europa. eu/. Eliquis (apixaban) - Súhrn charakteristických vlastností, august 2014. http://www.adcc.sk/web/humanne-lieky/lieky.html.
    14. Zalpour A, Oo TH. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Design, Development and Therapy 2014;8:2181-2191. Go to original source...
    15. Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015;13:15901596. Go to original source...

    Return to the content